New drug combo tested for aggressive brain tumors
NCT ID NCT03514069
Summary
This early-stage study is testing whether adding an experimental drug called ruxolitinib to standard brain cancer treatment (radiation and chemotherapy) is safe for patients. Researchers want to find the highest dose of ruxolitinib that patients can tolerate without severe side effects. The study involves 60 adults with newly diagnosed, aggressive brain tumors called high-grade gliomas or glioblastoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.